OBJECTIVE We assessed the influence of age on warfarin dose, percentage time in target range (PTTR), and risk of major hemorrhage. DESIGN Warfarin users recruited into a large prospective inception cohort study were categorized into three age groups: young (younger than 50 yrs), middle aged (50-70 yrs), and elderly (older than 70 yrs). The influence of age on warfarin dose and PTTR was assessed using regression analysis; risk of major hemorrhage was assessed using proportional hazards analysis. Models were adjusted for demographic, clinical, and genetic factors. SETTING Two outpatient anticoagulation clinics. PARTICIPANTS A total of 1498 anticoagulated patients. OUTCOMES Warfarin dose (mg/day), PTTR, major hemorrhage. RESULTS Of the 1498 patients, 22.8% were young, 44.1% were middle aged, and 33.1% were elderly. After accounting for clinical and genetic factors, compared with young warfarin users, warfarin dose requirements were 10.6% lower among the middle aged and an additional 10.6% lower for the elderly. Compared with young patients, middle-aged and elderly patients spent more time in target international normalized ratio (INR) range (p<0.0001), despite having fewer INR assessments (p<0.0001). Compared with young warfarin users, absolute risk of hemorrhage was marginally higher among the middle aged (p=0.08) and significantly higher among the elderly (p=0.016). Compared with young warfarin users, after adjustment, the relative risk of hemorrhage increased by 31% for each age category (p=0.026). CONCLUSIONS In a real-world setting, despite achieving better anticoagulation control, elderly patients had a higher risk of major hemorrhagic events. As the population ages and the candidacy for oral anticoagulation increases, strategies that mitigate the elevated risk of hemorrhage need to be identified. KEY WORDS age, warfarin dose, percentage time in target range (PTTR), major hemorrhage.
Oral anticoagulants are the main treatment modality for decreasing the risk of venous thromboembolism and thromboembolic events associated with atrial fibrillation (AF). 1 Despite the introduction of non-vitamin K antagonists (DOACs), warfarin remains the most widely used oral anticoagulant in the United States. 2, 3 Warfarin dosing has remained challenging because of its pronounced interindividual variability, narrow therapeutic index, drug and dietary interactions, 4 and potential for overanticoagulation leading to hemorrhagic complications. [5] [6] [7] Thus despite its efficacy, warfarin is underutilized, 8, 9 due in part to fear of bleeding episodes. 10 Anticoagulation-related bleeding is a frequent cause of adverse drug-related hospitalizations in the United States. 11 Increasing age is an important predictor of dose and a nonmodifiable risk factor for hemorrhage. [12] [13] [14] [15] As the population ages, the need for anticoagulation is expected to increase with the rise in age-related comorbidities. For instance, the prevalence of AF, the most common dysrhythmia, increases with age and is expected to reach 12.1 million by 2030. [16] [17] [18] In addition, patients with AF are five times more likely to experience an ischemic stroke and twice as likely to die compared with patients without AF. 19, 20 Therefore, the need for safe and effective anticoagulation in an aging population is of paramount importance. To this end, we examined the effect of age on dose, anticoagulation control, and major hemorrhagic events in warfarin users after accounting for clinical and genetic variables.
Methods

Study Population
Participants (20 yrs or older) initiating warfarin with the target international normalized ratio (INR) of 2.0-3.0 were enrolled in an inception cohort study with approval from the institutional review boards of the University of Alabama at Birmingham and Emory University. Patients requiring a target INR of 2.5-3.5 (e.g., mechanical heart valves) were excluded. 21, 22 Clinical and Genetic Variables
Patients managed at two oral anticoagulant clinics were approached and consented to enrollment in the study. Patient history was collected through a structured interview form and included information on demographics, indications for therapy, comorbidities, and medications as previously reported. [21] [22] [23] Information on factors related to lifestyle and socioeconomic status including smoking, alcohol use, physical activity, dietary vitamin K intake, education, annual household income, and medical insurance was also collected. Medical records were reviewed to verify the medical history of the patients.
Follow-up included monthly visits for up to 2 years from initiation of therapy. Information on factors that affect warfarin response were collected during these visits and included INR, concurrent medications, dietary vitamin K intake, alcohol use, and physical activity. Medication information was verified by medical record review as before, with emphasis on drugs that alter warfarin response including nonsteroidal antiinflammatory drugs, antiplatelet agents, and CYP2C9 inhibitors, inducers, or substrates.
In addition to clinical data, patients were genotyped for warfarin-specific polymorphisms. 21, 22 Blood samples were collected during the enrollment visit, and DNA extracted using the Gentra PureGene system (Gentra Sys, Inc., Minneapolis, MN, USA). VKORC1 (rs99232 31), CYP2C9 [*2 (rs1799853), *3 (rs1057910)], CYP4F2 (rs2108622), and African-American specific CYP2C9 single nucleotide polymorphisms (SNPs) [*5 (rs28371686), *6 (rs9332131), *11 (rs28371685)], and the CYP2C SNP rs12777823 were genotyped. [21] [22] [23] [24] [25] [26] Outcome Definitions
Warfarin dose (mg/day; log transformed to attain normality) was defined as the average maintenance dose after the attainment of three consecutive INRs in target range measured at least 2 weeks apart, as previously defined. 24, 25, 27, 28 Proportion of Time Spent in Target Range and Quality of Anticoagulation Control For each patient, proportion of time spent in target range (PTTR) was calculated as the percentage of interpolated INR values within the target range of 2.0-3.0 after attainment of first INR in target range using the Rosendaal linear interpolation method. 29 We also present proportion of time spent below (PTBR) and above (PTAR) target range.
Because PTTR is a recognized risk factor for hemorrhage, we categorized patients' quality of anticoagulation control based on cumulative PTTR in two ways. First, we considered PTTR 60% or higher (vs lower than 60%) because this was evaluated as a predictor of hemorrhage in warfarin users in recent clinical trials and was also included in the recently proposed HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR [defined as PTTR lower than 60%], Elderly, Drug consumption/alcohol abuse) score. 30 Second, because the effectiveness of warfarin compared with the newer oral anticoagulants is related to the level of PTTR achieved, we also categorized PTTR as poor anticoagulation control (PTTR lower than 60%), good control (60-70%), and excellent control (PTTR 70% or higher).
31-34
Major Hemorrhage
As previously defined, 35 major hemorrhages included fatal bleeding and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular retroperitoneal, intraarticular, or pericardial, or intramuscular with compartment syndrome, and/or bleeding with a fall in hemoglobin level of 2 g/ dl or more, or leading to transfusion of 2 units or more of whole blood or red cells. Because the focus of this article was to evaluate the association of age on risk of major hemorrhages, minor hemorrhages (mild nosebleeds, microscopic hematuria, mild bruising, and mild hemorrhoidal bleeding) were not included in the analysis. During the 2-year follow-up, for all major hemorrhagic complications, the complication site (e.g., endoscopy of gastrointestinal tract), severity of the event (e.g., requiring transfusion, surgical intervention), and laboratory findings (e.g., INR, hemoglobin/hematocrit) at the time of the event were documented objectively. Isolated subtherapeutic or supratherapeutic INRs in the absence of evidence of bleeding were not classified as events. The Alabama Center for Health Statistics was queried to verify cause of death for all deceased to ensure inclusion of deaths due to hemorrhagic complications. All complications were adjudicated independently by the medical director of the Anticoagulation Clinic. Only medically documented adjudicated events were included in the analyses, as previously reported. 27, [36] [37] [38] Statistical Analyses Analysis of variance was used to assess group differences for continuous variables and v 2 for categorical variables. All SNPs were tested for the Hardy-Weinberg equilibrium assumption by calculating the allele as well as genotype frequencies and using a v 2 exact test. First, we evaluated the univariate association of age with warfarin dose, PTTR, and risk of hemorrhage. These results informed the age categorization for subsequent adjusted analyses as young (younger than 50 yrs), middle aged (50-70 yrs), and elderly (older than 70 yrs). We then evaluated the effect of age (young, middle aged, elderly) on warfarin dose and PTTR using multivariable linear regression analysis. The influence of age on the risk of major hemorrhage was assessed using the counting process format in the proportional hazards model. The models were adjusted for demographic (i.e., sex, race, body mass index [BMI]), lifestyle (i.e., smoking), clinical comorbid conditions (i.e., kidney impairment [categorized as estimated glomerular filtration rate (eGFR) higher than 60, 30-59, lower than 30 ml/min/1.73 m 2 ]), medication use (i.e., antiplatelet), or genetic (i.e., CYP2C9, CYP4F2, VKORC1, and rs12777823) factors. We included factors that showed significant differences in prevalence by age in our cohort and retained these factors in the model at a nominal p value of 0.2 or lower. All analyses were performed using SAS v.9.3 (SAS Institute Inc., Cary, NC, USA) at a nondirectional a level of 0.05.
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Results
Of the 1498 patients (48% women, 44% African American) included in the analysis, 341 (23%) were younger than 50 years (young), 661 (44%) were between 50 and 70 years (middle aged), and 496 (33%) were older than 70 years (elderly). Table 1 shows participant characteristics by age groups.
Compared with young warfarin users, the middle-aged and elderly patients had lower warfarin dose requirements (p<0.0001) and lower eGFR (p<0.0001). When compared with younger and middle-aged groups, the elderly group consisted of a significantly higher proportion of women (p=0.048) and European 590 PHARMACOTHERAPY Volume 38, Number 6, 2018
Americans (p<0.0001), and they were more likely to be on warfarin due to AF (p<0.0001). The younger patients were more likely to be African American and be on warfarin for venous thromboembolism (p<0.0001). ). Similarly, the concurrent use of statins (p<0.0001), antiplatelet agents (p<0.0001), and amiodarone (p=0.001) was highest among the elderly. The assumption of the Hardy-Weinberg equilibrium was met for all SNPs (p>0.20). The prevalence of genetic factors known to influence warfarin response did not vary by age group except for the VKORC1 (p<0.0001) and CYP2C9*3 variants (p=0.01) that were more prevalent in the elderly. Genotype information was not available in 93 patients for CYP2C9, 45 patients for VKORC1, 197 for CYP4F2, and 198 for rs12777823 because these samples had not been genotyped. The VKORC1 variant (À1639 C>T) includes "TT or CT," CYP4F2 variant includes "AG or AA," and the rs12777823 variant includes "AG or GG."
After accounting for clinical and genetic factors, compared with young patients, warfarin dose requirements were 10.6% lower among the middle aged and an additional 10.6% lower for the elderly patients. Sex did not influence warfarin dose requirements. Warfarin dose requirements were lower among patients possessing the CYP2C9, VKORC1, and rs12777823 variant, among African Americans, in patients with CKD, congestive heart failure, and those on concurrent amiodarone therapy. In contrast, higher BMI, venous thromboembolism, and possession of the CYP4F2 variant were associated with higher warfarin dose requirements. The final dosing algorithm by age after incorporating clinical and genetic factors is presented in Table 2 .
Overall PTTR in the study cohort was 52.4% (AE 22.5%). Young patients spent more time below range (PTBR, p<0.0001) compared with the middle aged and elderly ( Patients achieving a PTTR of 60% or higher over the treatment period are considered to have good anticoagulation control, and those achieving a PTTR of 70% or higher are considered to have excellent anticoagulation control. Young warfarin users were less likely to achieve these metrics for anticoagulation control compared with the middle-aged (p<0.0001) and elderly (p<0.0001) warfarin users (Table 3 , Figure 1B) .
Over 2050 person-years of follow-up, 173 major hemorrhagic events were encountered (incidence rate 8.44, 95% confidence interval [CI] 7.25-9.77). Major hemorrhages by site included gastrointestinal (104), genitourinary (22) , retroperitoneal (7), intracranial bleeds (15), hemoptysis (5), and hematomas (20) . Incidence rates were lowest in the young warfarin users and highest among the elderly (Table 3) . Compared with young warfarin users, the incidence rate ratio (IRR) of hemorrhage was marginally higher among the middle aged (IRR 1.5, 95% CI 0.95-2.56, p=0.08) and significantly higher among the elderly (IRR 1.8, 95% CI 1.12-3.0, p=0.016).
After adjusting for race, sex, BMI, hypertension, CKD, PTTR (lower than 60% vs 60% or higher), genetic factors, concurrent antiplatelet, amiodarone, and statin therapy, the risk of hemorrhage increased by 31% for each age category (hazard ratio [HR] 1.31, 95% CI 1.03-1.66, p=0.026; Figure 1C ) when compared with young warfarin users. In addition to older age, AfricanAmerican race (HR 1.49, 95% CI 1.02-2.17, p=0.04), concomitant antiplatelet therapy (HR 1.64, 95% CI 1.14-2.36, p=0.008), hypertension (HR 1.70, 95% CI 1.07-2.71, p=0.025), CKD 
Discussion
We present a comprehensive look at warfarin response among young (younger than 50 yrs), middle-aged (50-70 yrs), and elderly (older than 70 yrs) warfarin users from a large prospective cohort study. We demonstrate that middle-aged patients need a 10% warfarin dose reduction, and the elderly need an additional 10% warfarin dose reduction after accounting for clinical and genetic factors. Assessment of anticoagulation control (PTTR) showed that middle-aged and elderly patients have better anticoagulation control compared with young warfarin users, and a higher proportion of these patients also achieve good (PTTR higher than 60%) and excellent control (PTTR higher than 70%). Furthermore, evaluation of the age and hemorrhage association indicated that elderly patients have a higher risk of major hemorrhage despite achieving better anticoagulation control.
Our study found a significant inverse association between age and warfarin dose, a finding consistent with existing literature.
12-15 Warfarin dose reductions in prior studies have ranged from 8-21% per decade of life, whereas evaluation of age on a continuous scale was shown to result in a weekly warfarin dose decrease of 0.4 mg per year of aging. [12] [13] [14] [15] Thus older patients are more sensitive to warfarin compared with younger patients. Age-related changes in drug response are multifactorial with a decline in clearance, albumin binding, or renal excretion contributing to pharmacokinetic changes. [38] [39] [40] Moreover, the increase in comorbid conditions and concomitant medication use in the elderly may influence warfarin response in complex ways through drug-drug and drug-disease interactions. This is illustrated by the multitude of factors that influence warfarin dosing, several of which are now included in the warfarin dosing algorithm.
Several factors significantly associated with warfarin dose in the current study are also part of the commonly used warfarin dosing algorithm just cited and have been established as important predictors of warfarin dose and response. Our own research group has previously reported on the associations of kidney function, 25 left ventricular systolic dysfunction, 41 and the CYP2C9, 21, 22 VKORC1, 22, 23 and CYP4F2 27 variants with warfarin dose. We also evaluated the differential effect of self-reported race on warfarin, reporting on the variable effect of genetic and nongenetic factors on warfarin dose and hemorrhage by race. 28, 36 However, the effect of age on warfarin dose was similar across race groups in our study. 28 Age is also an important predictor of bleeding outcomes among warfarin users and has been incorporated into several bleeding risk scores. 30, [42] [43] [44] However, comparison of the different scores show variability in classification across risk categories and only modest improvements in the ability to predict bleeding outcomes. 45, 46 Moreover, the age cutoffs across these models are not consistent, making it difficult to establish a fixed age threshold for assessing bleeding risk. A recent evaluation demonstrated that the HAS-BLED score performed better compared with the ATRIA or ORBIT scores because it incorporates PTTR. 46 A significant body of evidence supports that poor anticoagulation control (PTTR lower than 60%) is a predictor for hemorrhage among warfarin users. [31] [32] [33] [34] Moreover, PTTR of 60% or greater is widely recognized as the accepted quality metric for anticoagulation management services and is incorporated into risk prediction rules. The consistency of the influence of PTTR on risk of hemorrhage was also demonstrated in the recent DOAC clinical trials. 34, 47 For instance, compared with dabigatran (150-mg dose), the risk of hemorrhage was higher for warfarin users with PTTR lower than 57%, similar among warfarin users with PTTR 57-72%, and lower among those with PTTR higher than 72%. 34 In our study, older patients had significantly higher PTTR compared with younger patients but also had a higher risk of major hemorrhagic events despite attaining better anticoagulation control. One study 48 demonstrated that at very high PTTR (more than 70), where almost all patients have achieved a therapeutic INR of 2.0-3.0, PTTR was not correlated to warfarin-related complications in patients with AF. In this scenario, factors other than PTTR such as poor hypertension control may potentially be responsible for the high hemorrhagic risk. Another possible explanation may be age-related frailty where the deterioration in normal bodily functions plays a role in precipitating adverse outcomes. 49, 50 Although aiming for a lower INR target range (1.6-2.6) in patients older than 70 years may reduce the bleeding risk, 51, 52 it may also limit effectiveness. 53 Based on current evidence, the benefits of warfarin therapy (INR 2-3) still outweigh the risks even in elderly patients. 8, 54 Although this was a large prospective inception cohort study, we recognize its limitations. It was neither feasible nor possible to control for all potential confounders such as over-the-counter medication use, episodic use of antibiotics, dietary vitamin K intake, rare genetic variants, and gene-gene, gene-environmental interactions. Given the efficacy of warfarin, the incidence of thromboembolic events among patients on warfarin in our cohort was low. As a result, we were unable to assess the benefit versus risk of warfarin across the three age categories. However, anticoagulation control can serve as a practical surrogate for the actual thromboembolic events because it is always the goal for any anticoagulation therapy to attain target INR. All patients in our study were able to achieve a target INR of 2.0-3.0; however, this prevented us from assessing whether a lower INR range would result in a lower risk of hemorrhage. Finally, as in all observational studies, caution in ascribing the observed effects as causal is prudent.
Conclusion
Despite achieving better anticoagulation control, elderly patients on warfarin had a higher risk of major hemorrhagic events as compared with younger patients. Strategies to mitigate the hemorrhagic risk while maintaining the risk reduction in thromboembolic events are needed. As the population ages and the candidacy for oral anticoagulation increases, identifying reliable strategies that enable protection against adverse bleeding events would be impactful.
